Capricor Therapeutics Stock Forecast
Weaker technical forecast for Capricor Therapeutics as stock downgraded to Sell Candidate.
(Updated on May 26, 2023)
The Capricor Therapeutics stock price fell by -3.01% on the last day (Friday, 26th May 2023) from $4.65 to $4.51. It has now fallen 3 days in a row. During the last trading day the stock fluctuated 7.04% from a day low at $4.41 to a day high of $4.72. The price has risen in 6 of the last 10 days and is up by 11.91% over the past 2 weeks. Volume has increased on the last day by 50 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 83 thousand shares were bought and sold for approximately $374.94 thousand.
Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.
The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $4.72 will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall -8.53% during the next 3 months and, with a 90% probability hold a price between $3.32 and $4.32 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.
CAPR Signals & Forecast
The Capricor Therapeutics stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $4.62. On a fall, the stock will find some support from the long-term average at approximately $4.19. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Tuesday, May 23, 2023, and so far it has fallen -4.85%. Further fall is indicated until a new bottom pivot has been found. Capricor Therapeutics gained volume on the last day, but on falling prices. In technical terms, this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-offs".
Support, Risk & Stop-loss for Capricor Therapeutics stock
Capricor Therapeutics finds support from accumulated volume at $4.29 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.311 between high and low, or 7.04%. For the last week, the stock has had daily average volatility of 4.50%.
Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.
Trading Expectations (CAPR) For The Upcoming Trading Day Of Tuesday 30th
For the upcoming trading day on Tuesday, 30th we expect Capricor Therapeutics to open at $4.55, and during the day (based on 14 day Average True Range), to move between $4.29 and $4.73, which gives a possible trading interval of +/-$0.217 (+/-4.82%) up or down from last closing price. If Capricor Therapeutics takes out the full calculated possible swing range there will be an estimated 9.63% move between the lowest and the highest trading price during the day.
Since the stock is closer to the resistance from accumulated volume at $4.64 (2.88%) than the support at $4.29 (4.88%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.
Is Capricor Therapeutics stock A Buy?
Capricor Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Sell candidate.
Current score: -1.596 Open Broker Account
Sell Candidate DowngradedPredicted Opening Price for Capricor Therapeutics of Tuesday, May 30, 2023
The predicted opening price is based on yesterday's movements between high, low, and closing price.
| Fair opening price May 30, 2023 | Current price |
|---|---|
| $4.55 | $4.51 (Undervalued) |
Remember To Visit Our YouTube Channel
Trading levels for CAPR
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 4.86 | 7.70 % | |
| R2 | 4.74 | 5.07 % | ||
| R1 | 4.67 | 3.45 % | ||
| Current price: | 4.51 | |||
| Support | S1 | 4.43 | -1.81 % | |
| S2 | 4.35 | -3.44 % | ||
| S3 | 4.24 | -6.07 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 5.03 | 11.53 % | |
| R2 | 4.98 | 10.42 % | ||
| R1 | 4.64 | 2.88 % | ||
| Current price | 4.51 | |||
| Support | S1 | 4.29 | -4.88% | |
| S2 | 4.19 | -7.10% | ||
| S3 | 4.03 | -10.64% |
FAQ
Click here for our free guide on how to buy Capricor Therapeutics Stock.
About Capricor Therapeutics
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Ph... CAPR Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
